Start Over

[Therapy-related acute leukemia: study of 23 pacients].

Authors :: Motlló C
Sancho JM
García O
Granada I
Millá F
Ribera JM
Source :: Medicina clinica [Med Clin (Barc)] 2011 Oct 15; Vol. 137 (10), pp. 449-52. Date of Electronic Publication: 2011 Jun 22.
Publication Year :: 2011
Abstract: Background and Objective: The growing use of antineoplastic treatments has led to an increase in the incidence of therapy-related leukemias (TRL). The objective was to describe the characteristics of TRL.<br />Patients and Methods: Twenty-three cases of TRL were registered. Chemotherapeutic agents used for the first tumor, time interval, clinical and biological characteristics, treatment and prognosis of the TRL were analyzed.<br />Results: Median age was 61 years. Cytotoxic agents used in previous neoplasm consisted of alkylating agents (17 patients), inhibitors of DNA topoisomerase II (14), antitubulin agents (12), radiotherapy (9, in 6 with radiotherapy) and antimetabolites (6). Median time from diagnosis of the first neoplasm to TRL was 3 years (range 1.2-15.8). Thirteen patients received intensive chemotherapy [with stem cell transplantation (SCT) in 3] and the other 10 received symptomatic treatment (median survival 3 years versus 0.079 years, P=0.004).<br />Conclusions: In this study, TRL were associated with exposure to alkylating agents, antitubulin agents and topoisomerase II inhibitors. Response to treatment and prognosis were poor, although chemotherapy and SCT may prolong survival.<br /> (Copyright © 2010 Elsevier España, S.L. All rights reserved.)